Catalysts for $ABBV
477 tracked
Jun 5, 2023
approval
ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE) — FDA approval
ORIAHNN (COPACKAGED)
→
Jun 5, 2023
approval
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
May 18, 2023
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
May 18, 2023
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
May 18, 2023
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Apr 17, 2023
approval
QULIPTA (ATOGEPANT) — FDA approval
atogepant
→
Apr 10, 2023
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Feb 24, 2023
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Feb 24, 2023
approval
DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Feb 24, 2023
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Dec 19, 2022
approval
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Dec 16, 2022
approval
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Dec 8, 2022
approval
PRED MILD (PREDNISOLONE ACETATE) — FDA approval
prednisolone acetate
→
Dec 8, 2022
approval
PRED MILD (PREDNISOLONE ACETATE) — FDA approval
prednisolone acetate
→
Oct 21, 2022
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Sep 23, 2022
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Sep 23, 2022
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Aug 24, 2022
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Aug 24, 2022
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Aug 24, 2022
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Aug 24, 2022
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Aug 24, 2022
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Aug 24, 2022
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Aug 24, 2022
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Jun 16, 2022
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 16, 2022
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 15, 2022
approval
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
May 11, 2022
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
May 11, 2022
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Apr 29, 2022
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→